These findings strongly suggest for the first time that the Src inhibitor dasatinib preferentially decreased the proportion of ALDH1-positive, putative breast cancer stem cells in breast cancer cells of the basal B subtype. Here, ALDH1A1 is linked to breast carcinoma.